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Summary
The macrophage migration inhibitory factor (MIF) re-
ceptor (CD74) was cloned recently, but the signaling
mechanism is not evident. We hypothesized that sig-
naling requires an additional molecule such as CD44,
which activates nonreceptor tyrosine kinases. We uti-
lized the CD74- and CD44-deficient COS-7/M6 cell to
create stable transfectants expressing CD74, CD44,
and a truncated CD44 lacking its intracytoplasmic
signaling domain. CD74 alone mediated MIF binding;
however, MIF-induced ERK1 and ERK2 kinase phos-
phorylation required the coexpression of full-length
CD44. MIF binding was associated with the serine
phosphorylation of CD74 and CD44. Investigations
that used siRNA or kinase inhibitors indicate that
MIF-induced ERK1 and ERK2 activation through
CD44 required the Src tyrosine kinase. Studies of
CD74, CD44, and CD74-CD44 transformants and corre-
sponding mutant cells showed that CD74 and CD44
were necessary for MIF protection from apoptosis.
These data establish CD44 as an integral member
of the CD74 receptor complex leading to MIF signal
transduction.
Introduction
Macrophage migration inhibitory factor (MIF) is an up-
stream activator of innate immunity that regulates sub-
sequent adaptive responses (Bacher et al., 1996; Calan-
dra and Roger, 2003). MIF antagonizes the action of
glucocorticoids (Calandra et al., 1995; Calandra and
Roger, 2003), upregulates Toll-like receptor 4 (TLR-4)
expression (Roger et al., 2001), controls Jab1 transcrip-
tional effects (Kleemann et al., 2000), and suppresses
activation-induced, p53-dependent apoptosis (Hudson
et al., 1999; Mitchell et al., 2002; Nguyen et al., 2003).
This latter action may sustain inflammatory responses
in the face of activation-induced apoptosis, and it may
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of Medicine, Durham, North Carolina 27710.underlie MIF’s broad inflammatory and proproliferative
effects on diverse cell types (Hudson et al., 1999;
Mitchell et al., 2002; Fingerle-Rowson et al., 2003; Leech
et al., 2003).
Interest in the biology of MIF has been heightened by
the protein’s role in septic shock (Bernhagen et al., 1993;
Calandra et al., 2000), by the description of functional
polymorphisms in the gene that are associated with in-
flammatory disease (Gregersen and Bucala, 2003), and
by an emerging role for MIF in tumorigenesis (Meyer-
Siegler and Hudson, 1996; Hudson et al., 1999; Fin-
gerle-Rowson et al., 2003). A cell-surface receptor for
MIF was cloned in 2003 and identified as the widely ex-
pressed Type II transmembrane protein, CD74 (Leng
et al., 2003). Known features of MIF signal transduction
include the phosphorylation of the ERK1 and ERK2
MAP kinases, which may be sustained in certain circum-
stances (Mitchell et al., 1999). In addition, MIF activates
the ERK effectors cytoplasmic phospholipase A2, which
initiates arachidonic metabolism and has a role in p53
suppression (Mitchell et al., 2002), and the Elk-1 and
Ets transcription factors, which regulate TLR4 expres-
sion (Roger et al., 2001). MIF-dependent ERK activation
also promotes maximal expression of cyclin D1 leading
to cyclin-dependent kinase activation, RB phosphoryla-
tion, and adhesion and/or growth factor stimulation of
mesenchymal cells (Liao et al., 2003; Swant et al., 2005).
In an initial report, evidence was provided for a high-
affinity binding interaction between MIF and the CD74
ectodomain (Kd w9 3 1029) (Leng et al., 2003). Like
MIF, CD74 is expressed as a homotrimer, but the precise
mechanism by which signal transduction proceeds by
MIF engagement of CD74 is unknown. The CD74 intra-
cellular domain is only 46 amino acids long and it lacks
homology with tyrosine or serine/threonine kinases, or
with the interaction domains for nonreceptor kinases
or nucleotide binding proteins. The intracytoplasmic
tail of CD74 nevertheless may undergo phosphorylation
(Anderson et al., 1999), and there are data supporting
a pathway for this protein’s regulated, intramembrane
cleavage (Matza et al., 2002). Two studies also have
reported a functional, cell-surface association between
CD74 and CD44 (Naujokas et al., 1993, 1995), which
has known tyrosine kinase activation properties (Turley
et al., 2002). In the present study, we explored the pos-
sibility that MIF signaling through CD74 requires the si-
multaneous expression and activation of CD44. We per-
formed studies in cell lines engineered to stably express
CD74 or CD44, their combination, or CD74 together with
a truncated CD44 lacking its cytoplasmic signaling do-
main (CD44D67). We also investigated the responses of
primary cells genetically deficient in CD74 or CD44.
Results
Creation and Characterization of Stably Expressing
CD74 and CD44 Transformants
Mammalian COS-7 cells do not bind MIF unless engi-
neered to express CD74 (Leng et al., 2003), and the
COS-7/M6 subline additionally is CD44 deficient (Jiang
Immunity
596Figure 1. Schematic Diagram of the Struc-
tures of the Human CD74 and CD44 Proteins
Used to Create Stable Cell Lines
IC, TM, and EC are the intracellular, trans-
membrane, and extracellular domains, re-
spectively. The locations of the known intra-
cytoplasmic serine phosphorylation sites
are indicated.et al., 2002). The absence of CD74 and CD44 was con-
firmed in COS-7/M6 cells by immunoblotting, and the
cells then were used as hosts for the stable transfection
of plasmid DNA encoding full-length human CD74 (1–
232 aa), full-length CD44 (1–361 aa of the hematopoietic
‘‘H’’ isoform of CD44), or a truncated CD44 lacking its
cytoplasmic domain (CD44D67) (Figure 1). Cell lines ex-
pressing the corresponding cDNAs were propagated,
subcloned, and selected for further study based on the
stable expression of these proteins (Figure 2A). We con-
firmed the cell-surface expression of the transfected
proteins by flow cytometry. We also verified equivalent
surface expression of the full-length and truncated
forms of CD44, which is important for functional analy-
ses, and confirmed that expression of the MIF binding
receptor, CD74, was not influenced by the presence of
CD44 or CD44D67 (Figure 2B).
We first utilized these stable cell lines to assess the
potential contribution of CD44 to the MIF binding inter-
action with CD74. We prepared an Alexa 488, fluores-
cently labeled MIF that was used previously in the ex-
pression cloning of CD74 (Leng et al., 2003), and we
tested its binding activity with the different transfected
cell lines (Figure 2C). These data supported the conclu-
sion that CD74 alone is sufficient to mediate MIF binding
to cells. CD44 alone did not bind MIF, nor did CD44
confer additional binding above that provided by CD74
alone.
CD44 Is Required for MIF-Mediated ERK
Phosphorylation
The phosphorylation of the ERK1 and ERK2 subfamily of
MAP kinases is an established feature of MIF signal
transduction (Mitchell et al., 1999; Lacey et al., 2003;
Amin et al., 2003). Initial studies showed that the COS-
7–CD74+CD44 cells responded to MIF stimulation, and
in accord with prior work (Lue et al., 2006), the response
was ‘‘bell shaped’’ and dose dependent (Figure 3A). We
then examined ERK phosphorylation in the different
transfected cell lines over time in response to a maximal
stimulatory concentration of MIF and showed MIF in-
duced ERK phosphorylation only in those cells that ex-
pressed both CD74 and full-length CD44 (Figure 3B). Al-
though MIF could induce a sustained pattern (>90 min)
of ERK1 and ERK2 phosphorylation in some cell types
(Mitchell et al., 1999; Liao et al., 2003), this was not ob-
served in the stable COS-7/M6 expression system.
ERK phosphorylation decayed at 30 min, which may
be due to the absence of adhesion signals that mediatethe sustained phase of activation (Liao et al., 2003;
Swant et al., 2005). Stable transfection of CD74 and
CD44 did not affect the baseline sensitivity of COS-7/
M6 cells to non-MIF stimuli, as assessed by an experi-
ment in which no differences in ERK phosphorylation
in untransfected versus transfected cells was observed
after 10% serum stimulation (see Figure S1 in the Sup-
plemental Data available online).
We verified the requirement for CD44 in MIF signal
transduction by examining primary cells prepared from
wild-type, CD74-deficient, and CD44-deficient mice.
Wild-type murine embryonic fibroblasts (MEFs) express
both CD74 and CD44 (Figure S2) and responded to MIF
by ERK phosphorylation (Figure 3C). MIF induced ERK
phosphorylation only in wild-type cells, and not in cells
genetically deficient in CD74 or CD44. Similar results
were obtained in peritoneal macrophages (Figure S3).
We did not obtain evidence for a cell-surface interac-
tion between CD44 and MIF (Figure 2C). However, CD44
might mediate signaling of MIF by binding to a MIF that
has undergone conformational modification as a result
of binding to CD74. As a test of this possibility, we pre-
pared soluble, recombinant CD74 ectodomain (sCD74)
that binds MIF with a Kd w9 3 1029 (Leng et al., 2003)
and added increasing concentrations of preformed
MIF-sCD74 complexes to cells expressing CD44 alone
(Figure 3D). No increase in ERK phosphorylation was
observed under these conditions, supporting the re-
quirement for an interaction between membrane-ex-
pressed CD74 and CD44. We also tested the possibility
that CD44 may be activated in trans by a MIF-CD74
complex by examining MIF-induced ERK phosphoryla-
tion in 1:1 mixtures of the CD74- or CD44-expressing
COS-7/M6-derived cell lines. An MIF-induced increase
in ERK phosphorylation was not detected in these mix-
ing experiments (Figure 3E). These data, taken together,
are consistent with the interpretation that MIF-induced
ERK phosphorylation requires the cellular expression
of two integral membrane proteins: a binding receptor
(CD74) and a signaling protein (CD44).
MIF Modulates the Serine Phosphorylation
of CD74 and CD44
Two serine residues within the CD74 intracytoplasmic
domain (Ser6 and Ser8) undergo phosphorylation in
a protein kinase-dependent manner (Anderson et al.,
1999). We quantified the content of phospho-serine res-
idues in CD74 by a specific sandwich ELISA (Perez et al.,
2003) and found the phosphorylation of CD74 in the
CD44 Mediates MIF Signaling
597Figure 2. Analysis of COS-7/M6 Cells Stably Transfected with CD44, CD74, CD74+CD44, or CD74+CD44D67
(A) Cell lysates were immunoblotted with human CD44 and human CD74 antibodies. CD44 cannot be distinguished from CD44D67 by molecular
weight because of posttranslational glycosylation (Jiang et al., 2002).
(B) Cell-surface expression of COS-7/M6 cell controls or COS-7/M6 cells expressing CD44, CD74, CD74+CD44, or CD74+CD44D67. Flow cytom-
etry was performed after incubation of 53 104 cells at 0C with FITC-labeled anti-CD44 or anti-CD74. Each analysis included an isotypic control.
(C) Flow cytometry analysis of Alexa-MIF binding to COS-7/M6 cells and COS-7/M6 cells stably transfected with CD44, CD74, or CD74+CD44.
Each panel shows the fluorescence profile of 5 3 104 cells incubated at 0C for 30 min with Alexa-MIF. Control studies showed specific com-
petition of Alexa-MIF binding by unlabeled MIF (253 excess) or by anti-CD74 (clone LN2, 50 mg/ml) (Leng et al., 2003, and data not shown).
In all figure labels, COS-7 cells refers to the CD74- and CD44-deficient COS-7/M6 line. Numerical values show the MFI6 SD (p values by unpaired
t test).COS-7–CD74+CD44 cell line and in wild-type MEFs in-
creased in response to MIF, but it did not change in
the other COS-7/M6 transformants and genetically defi-
cient, primary cell lines (Figure 4A). The observation that
the phosphoserine content of CD74 increased only in
cells that expressed CD74 and full-length CD44 is con-
sistent with the hypothesis that the MIF-mediated phos-
phorylation of CD74 is dependent on the activity of the
CD44 intracytoplasmic domain.
Protein kinase A (PKA) has been implicated in the MIF-
dependent phosphorylation of ERK leading to down-
stream activation events (Mitchell et al., 1999). We
tested the potential role of PKA and PKC, which may
phosphorylate CD74 in vitro (Anderson et al., 1999), by
analyzing MIF-induced CD74 phosphorylation in thepresence of the PKA inhibitor, H-89, or the PKC inhibitor,
RO-31-2880. MIF stimulation of CD74 phosphorylation
decreased markedly upon PKA inhibition. No effect
was seen in the presence of the PKC inhibitor RO-31-
2880 at the effective and PKC-selective concentration
of 10 mM (Figure 4B; Padfield and Panesar, 1998; Hill
et al., 2003).
We also analyzed the effect of MIF stimulation on the
phosphorylation of CD44, which may occur on three
intracytoplasmic serine residues (Ser291, Ser316, and
Ser325) (Ponta et al., 2003; Thorne et al., 2004). Ser325
is constitutively phosphorylated in resting cells, but
undergoes dephosphorylation in response to PKC-acti-
vating stimuli. Conversely, Ser291 and Ser316 are
unphosphorylated in resting cells, but then may be
Immunity
598Figure 3. MIF-Induced ERK Phosphorylation Requires CD74 and Full-Length, Intact CD44
(A) Dose-dependent phosphorylation of ERK1 and ERK2 (ERK1/2) by MIF stimulation of the COS-7, CD74+CD44-expressing cell line.
(B) COS-7/M6 cells stably transfected with CD74, CD44, CD74+CD44, or CD74+CD44D67 were stimulated with MIF (100 ng/ml) for the indicated
times.
(C) Murine embryonic fibroblasts (MEFs) from wild-type mice, but not CD74-KO or CD44-KO mice, respond to MIF by ERK phosphorylation.
(D) Preformed MIF/CD74 complexes do not stimulate ERK phosphorylation in CD44-expressing COS-7/M6 cells. Recombinant sCD74 was in-
cubated with MIF overnight in a 3:1 molar ratio prior to addition to cells for 10 min. Epidermal growth factor (EGF) was used as a positive control
for ERK phosphorylation.
(E) COS-7 cells stably transfected with CD74+CD44, CD74, or CD44 were cocultured with the indicated cell line partner (13 106 of each cell type)
and MIF-induced ERK phosphorylation measured. The numerical ratio between phosphorylated to the total kinase protein was determined by
densitometric scanning of three experiments and expressed as a fold-change below each lane. The p values were calculated for each of the
comparisons (100, 50, and 10 versus 0 ng/ml MIF in [A], 100 versus 0 ng/ml MIF in [B] and [C] by the Student’s t test. ***p < 0.01, **p < 0.02,
*p < 0.05. The p values for comparisons with p > 0.05 are not displayed). KO, knockout.phosphorylated by the activation of PKC (Ser291) and
PKA (Ser316) (Legg et al., 2002; Ponta et al., 2003;
Thorne et al., 2004). We analyzed the effect of MIF stim-
ulation CD44 phosphorylation by sandwich ELISA with
a CD44 capture antibody to quantify CD44 phospho-ser-
ine residues (Perez et al., 2003). In contrast to the phos-
phoserine content of CD74, which increased in responseto MIF (Figure 4A), the net content of CD44 serine phos-
phorylation did not change after MIF stimulation (Fig-
ure 4C). We interpreted this result to be due either to
the lack of effect of MIF on CD44 serine phosphorylation
or, alternatively, to a mixed effect on CD44 phosphoryla-
tion and dephosphorylation such that net phosphoser-
ine content did not change. We obtained evidence for
CD44 Mediates MIF Signaling
599Figure 4. Phosphoserine Content of CD74 and CD44 Measured by ELISA
(A) COS-7/M6-derived cell lines and MEFs were treated with MIF (100 ng/ml) for 10 min and the cell lysates analyzed for phospho-serine by
a CD74-specific sandwich ELISA.
(B) The COS-7/CD74+CD44 cell line was pretreated with the protein kinase A (PKA) inhibitor, H-89 (20 mM), or the protein kinase C (PKC) inhibitor,
RO-31-28801 (10 mM), for 30 and 60 min prior to MIF (100 ng/ml) stimulation. Cell lysates then were analyzed for phospho-serine content.
(C) COS-7/M6-derived cell lines and MEFs were treated with MIF (100 ng/ml) for 10 min and the cell lysates analyzed for phospho-serine by
a CD44-specific sandwich ELISA.
(D) Analysis of CD44 phospho-serine content in control and MIF-stimulated, COS-7 cell lines after preincubation with the PKA inhibitor, H-89, or
the PKC inhibitor, RO-31-2880, for 30 min. Phosphoserine contents are expressed as relative absorbance values for ELISA of cell lysates for cell
treatment versus nontreatment. *p < 0.02 versus corresponding control.
(E) Western analysis of COS-7–CD74+CD44 cells after stimulation with MIF for 10 min. Cell lysates were probed for PKA and PKC with phospho-
specific and total PKA and PKC antibodies, *p < 0.01. KO, knockout.
Error bars denote the mean 6 SD.this second possibility by analyzing CD44 phosphoser-
ine content after stimulation in the presence of the pro-
tein kinase inhibitors. Under these conditions, the serine
phosphorylation of CD44 was reduced by PKA inhibition
(H-89, 20 mM) but not by PKC inhibition (RO-31-2880,
10 mM) (Figure 4D). A role for MIF activation of PKA
was confirmed by immunoblotting of the COS-7–
CD74+CD44-expressing cell line, which showed MIF-
dependent phosphorylation of PKA but not PKC (Fig-
ure 4E). These results suggest that MIF stimulation is
indeed associated with a PKA-dependent alteration in
the serine phosphorylation of CD44, but because the
net phosphoserine content is unaltered, there is a recip-rocal decrease in the amount of constitutively phos-
phorylated serines.
The Protein Tyrosine Kinase Src Is Activated by MIF
Engagement of the CD74-CD44 Complex
Members of the nonreceptor protein tyrosine kinase
family, c-Src (Src), may physically associate with the
intracytoplasmic domain of CD44 (Taher et al., 1996;
Bourguignon et al., 2001), leading to downstream ERK
phosphorylation via a Ras-Raf-MEK-dependent path-
way (Ishida et al., 1998; Migliaccio et al., 2000; Mahabe-
leshwar and Kundu, 2003). There is also recent evidence
for the activation of Src kinase family members by MIF,
Immunity
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the activation are unknown (Onodera et al., 2002; Amin
et al., 2006; Lue et al., 2006). We analyzed the phosphor-
ylation state of Src in the different COS-7/M6 transform-
ants and MEFs after MIF stimulation by immunoblotting
with a phospho antibody specific for Src (Tyr416). Src
kinase was phosphorylated by MIF treatment, but only
in the cells expressing both CD74 and full-length CD44
(Figures 5A and 5B).
To confirm a role for Src tyrosine kinase in MIF signal
transduction leading to ERK phosphorylation, we pre-
pared a short interfering RNA (siRNA) directed against
Src (Coluccia et al., 2006), and we tested its ability to
prevent the MIF-stimulated phosphorylation of Src and
ERK1 and ERK2. Treatment of COS-7–CD74+CD44-
expressing cells with Src-specific siRNA decreased
both Src protein expression and MIF-induced Src phos-
phorylation (Figure 5C). We also tested the potential ef-
fect of the Src kinase inhibitor PP2 (Salazar and Rozen-
gurt, 1999). PP2 addition to the COS-7–CD74+CD44 cell
line (Figure 5D) or to primary macrophages (Figure 5E)
resulted in an inhibition of the phosphorylation of Src
and ERK. These data are consistent with a role for a
CD44-associated Src kinase in MIF signal transduction
leading to ERK1/2 phosphorylation.
CD74 and CD44 Are Required for MIF-Mediated
Protection from p53-Dependent Apoptosis
An important biologic action of MIF is to sustain proin-
flammatory responses by inhibiting activation-induced,
p53-dependent apoptosis (Hudson et al., 1999; Mitchell
et al., 2002; Nguyen et al., 2003). We next asked whether
CD74 and CD44 were necessary for this action of MIF by
assessing the apoptotic response of the different COS-
7/M6 cell lines and primary macrophages genetically
deficient in CD74 or CD44. The COS-7/M6 cell lines
showed a brisk response to apoptotic induction, but
only in the case of the COS-7–CD74+CD44-expressing
cell line did MIF exert a significant protective effect (Fig-
ure 6A). The antiapoptotic action of MIF was associated
with a reduction in the intracytoplasmic content of a
Ser15-phosphorylated, p53 species (Figure 6B). MIF
protection from apoptosis of primary macrophages
also was found to be dependent on CD74 and CD44 (Fig-
ure 6C), and in these cells the protective effect of MIF
was almost complete, as in prior reports (Hudson
et al., 1999; Mitchell et al., 2002). MIF treatment of mac-
rophages during apoptosis induction also was associ-
ated with a diminution in the cellular content of Ser15-
phosphorylated p53 (Figure 6D). In contrast to reports
in a macrophage cell line (Mitchell et al., 2002) or in cul-
tured human synovial fibroblasts and mouse synovium
(Leech et al., 2003), however, we observed no effect of
MIF on total cellular p53 protein content.
Finally, we sought to examine the impact of the MIF–
CD74-CD44 signal transduction pathway in vivo by ex-
amining macrophage apoptosis in endotoxemic mice.
Wild-type, MIF-KO, CD74-KO, and CD44-KO mice
were primed with endotoxin (LPS), and their macro-
phages were harvested 1 day later by peritoneal lavage.
Initial assessment of macrophage viability by fluores-
cent-annexin staining showed that endotoxemic, wild-
type mice had a several-fold increase in apoptotic
macrophage numbers when compared to saline-treatedcontrols (Figure 6E). The apoptotic response was en-
hanced in the MIF-KO mice when compared to the
wild-type controls, which is in agreement with a prior re-
port (Mitchell et al., 2002), and apoptosis also increased
in the CD74-deficient and the CD44-deficient mouse
strains. Oligonucleosome ELISA analysis showed an
equivalent amount of LPS-induced apoptosis in macro-
phages isolated from the MIF-deficient, CD74-deficient,
and CD44-deficient strains that in turn was enhanced
when compared to wild-type controls (Figure 6F). These
data support a role for CD74 and CD44 in the MIF-medi-
ated protection of macrophage apoptosis in vivo.
Discussion
We provide support for an important role for CD44 in
MIF-mediated signal transduction through CD74. Prior
to the identification of MIF as an extracellular ligand
for CD74, there was evidence for an accessory function
for CD74 in immune stimulation that was mediated by an
interaction with CD44 (Naujokas et al., 1993). Given
CD74’s short intracytoplasmic domain and the absence
of motifs for second messenger activation, we hypothe-
sized that CD44 might be necessary for many, if not all,
of MIF’s signal transduction properties. By using COS-
7/M6 (deficient in both CD74 and CD44) cell lines engi-
neered to stably express combinations of CD74, CD44,
and CD44D67, we found that CD74 alone imparts MIF
binding to cells and that the presence of CD44 did not
confer additional binding activity over that of CD74
alone. Of note, evidence in support of a molecular com-
plex between MIF, CD74, and CD44 was provided by
Meyer-Siegler et al. (2004), who utilized an immunopre-
cipitation approach in cultured carcinoma cells. Our
data indicate that MIF induces the serine phosphoryla-
tion of the CD74 intracytoplasmic domain in a CD44-de-
pendent manner. This implies that although CD74 func-
tions to bind MIF, it also undergoes ligand-induced
activation events that may be necessary for the CD44-
dependent signaling pathways described herein or for
additional signaling mechanisms yet to be elucidated.
We did not obtain evidence for a specific interaction
between MIF and CD44; however, MIF-mediated ERK1
and ERK2 activation requires the expression of a full-
length CD44. MIF stimulation was associated with the
PKA-dependent serine phosphorylation of CD74 and
CD44. Investigations with siRNA and the kinase inhibitor
PP2 indicate that MIF-induced ERK activation proceeds
via the Src tyrosine kinase, which previously has been
shown to associate physically with the CD44 intracyto-
plasmic domain (Taher et al., 1996).
An important feature of MIF’s biologic action is its
ability to sustain monocyte/macrophage activation in
the face of activation-induced, p53-dependent apopto-
sis (Hudson et al., 1999; Mitchell et al., 2002). Apoptosis
and p53 studies of MIF-stimulated CD74, CD44, and
CD74/CD44 transformants and genetically deficient
primary cells are consistent with the conclusion that
CD74 and CD44 are necessary for MIF protection from
apoptosis. Endotoxemic MIF-deficient mice showed a
higher amount of macrophage apoptosis than wild-type
controls, which is in accord with prior work (Mitchell
et al., 2002), and the level of enhanced macrophage
CD44 Mediates MIF Signaling
601Figure 5. Src Tyrosine Kinase Mediates MIF-Induced ERK Phosphorylation
(A and B) COS-7/M6 derived cell lines (A) or MEFs (B) were stimulated with MIF for 10 min and the cell lysates analyzed for phospho-Src (p-Src,
Tyr416), GAPDH, phospho-ERK1 and ERK2 (p-ERK1/2), and total ERK1 and ERK2 (ERK1/2) by specific antibodies.
(C) COS-7/M6 cells expressing CD74+CD44 treated with siRNA directed against c-Src or a control siRNA prior to stimulation with MIF. Lysates
were analyzed for p-Src, total Src, GAPDH, and ERK by western blotting.
(D and E) COS-7/M6 cells expressing CD74+CD44 (D) or primary macrophages from wild-type mice (E) were treated with the kinase inhibitor,
PP2, for 60 min prior to MIF stimulation (10 min) and western blotting. Densitometric values below lanes refer to the ratio of phospho-protein
to total, reference protein, *p < 0.05, **p < 0.04, ***p < 0.01.
Immunity
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(A) COS-7/M6 cell lines were stimulated for apoptosis induction (AI) in the presence of MIF (100 ng/ml) for 24 hr, and the apoptotic response was
measured by caspase-3 activity (*p < 0.02, Student’s t test, two-tailed).
(B) Western blotting analysis of p53 in cytosolic fractions from the different COS-7 cell lines showing reduced phospho-p53 (p-p53) content in the
CD74+CD44 expressing cells after stimulation with MIF, *p < 0.02.
(C) Caspase-3 activity in primary macrophages after apoptosis induction in the presence of MIF (*p < 0.02, Student’s t test, two-tailed).
(D) Western blotting analysis of cytosolic fractions from primary mouse macrophages after apoptosis induction in the presence and absence of
MIF. Note that the murine (total) p53 antibody detects an immunoreactive, p53 doublet, which is consistent with previous observations (Mitchell
et al., 2002). Densitometric values below lanes refer to the ratio of phospho-protein to total p53 protein, *p < 0.02.
(E) Enhanced activation-induced apoptosis in macrophages from CD74-KO and CD44-KO mice. Wild-type, MIF-KO, CD74-KO, and CD44-KO
mice were injected i.p. with LPS, and macrophages were isolated from the peritoneal exudates 24 hr later. Representative high-power fields
of fluorescent-annexin stained macrophages are shown. The control image shows wild-type macrophages obtained from saline-treated
mice. For quantification, macrophages (53 104 cells per mouse, n = mice per experimental group) were examined in multiple high-power fields
and the positively stained cells (intense, punctate fluorescence) enumerated. No differences were observed between saline treatment of wild-
type, MIF-KO, CD74-KO, or CD44-KO (data not shown). *p < 0.01 versus saline-treated control (Student’s t test, two-tailed).
(F) Macrophage apoptosis quantified by oligonucleosome ELISA. The values shown are mean6 SD of triplicate wells and are representative of
two experiments. *p < 0.02 versus LPS-treated, wild-type mice, **p < 0.01 versus no LPS treatment (Student’s t test, two-tailed).
Error bars denote the mean 6 SD.apoptosis was recapitulated in mice lacking the MIF
binding (CD74) or signaling (CD44) receptor.
From the above data, we propose an MIF signal trans-
duction pathway based on evidence for the proximal in-
volvement of CD74 and CD44 (Figure 7). The respective
binding and signaling roles for CD74 and CD44 are rem-
iniscent of the signaling mechanism established for the
IL-6 family of cytokines, whereby a binding receptor
(i.e., IL-6Ra) associates with a transmembrane glyco-
protein (i.e., gp130) leading to kinase activation (Hibi
and Hirano, 2001). Several of the biologic activities ofMIF have been identified to proceed via ERK activation.
These include arachidonic acid metabolism and prosta-
glandin production (via cytoplasmic phospholipase A2
and cyclooxygenase-2) (Mitchell et al., 1999; Sampey
et al., 2001), regulation of p53 activity (Mitchell et al.,
2002), and the activation of additional ERK effectors,
such as the Ets family of transcription factors that regu-
late Toll-like receptor expression (Roger et al., 2001).
One question of interest is the precise role of CD74
and/or CD44 in additional features of MIF action, such
as its ability to bind to and regulate the intracytoplasmic
CD44 Mediates MIF Signaling
603Figure 7. Model of MIF Signal Transduction
Involving MIF Binding to CD74 and Activation
of the CD44 Coreceptor
The pathway leading from the CD44 intracy-
toplasmic domain through c-Src and toward
the activation of guanine nucleotide ex-
change factors (GEFs) has been described
(Bourguignon et al., 2001; Taher et al.,
1996). The pathway downstream of Ras has
been described (Mitchell et al., 1999; Lue
et al., 2006), and Swant et al. (2005) re-
cently reported a role for the Ras effector,
RhoGTPase, acting via myosin light chain
kinase (MLCK) and focal adhesion kinase
(FAK), in the induction of sustained phase,
MIF-mediated ERK activation.action of c-Jun activation domain binding protein-1
(JAB1). (Kleemann et al., 2000). Whether CD74 mediates
MIF internalization and/or facilitates interaction with
JAB1 will be important to consider. Recent information
suggests that JAB1 regulates the sustained phase of
MIF-induced ERK phosphorylation via activation of
a Src family kinase member (Lue et al., 2006). Sustained
ERK phosphorylation by MIF also exhibits adhesion de-
pendence (Liao et al., 2003), which may now be better
understood given CD44’s known role in matrix inter-
action (Bourguignon et al., 2001; Ponta et al., 2003).
Mitchell et al. also have established that cell adhesion
results in an autocrine MIF release response and to
a pathway for ERK activation involving the sequence
of Rho GTPase, myosin light chain kinase, and focal
adhesion kinase (Liao et al., 2003; Swant et al., 2005).
The present data also add to the emerging cellular bi-
ology of CD74 and CD44. CD74 has been shown to un-
dergo regulated intramembrane cleavage in B lympho-
cytes, leading to the activation of transcription by the
p65-RelA homodimer (Matza et al., 2001, 2002; Starlets
et al., 2006). Whether MIF participates as a ligand in
these events is presently under examination (I. Shachar,
personal communication). Notably, CD74-KO and MIF-
KO mice share phenotypic features, such as an impair-
ment in T helper 2 cell responses that may be attribut-
able, in part, to deficiencies in maturation of an adaptive
immune response (Topilski et al., 2002; Mizue et al.,
2005). CD44 is a genetically polymorphic molecule
with an important role in cell-extracellular matrix interac-
tion (Ponta et al., 2003). A potential overlapping functionfor CD44 and MIF, in addition to survival and antiapop-
totic functions (Allouche et al., 2000; Chen et al., 2001),
include proinflammatory actions for CD44 when en-
gaged by an activating antibody or by hyaluronan frag-
ments. In studies reminiscent of MIF biologic function,
however, many of these observations emphasize the
regulatory nature of CD44 (Bradbury, 2002; Teder
et al., 2002; Webb et al., 1990; Sun et al., 2001). Finally,
pharmacologic strategies directed at MIF are in preclin-
ical development (Lolis and Bucala, 2003). Closer con-
sideration of antireceptor strategies that target the
CD74/CD44 interaction may offer a basis for enhanced
therapeutic specificity.
Experimental Procedures
Mice and Primary Cells
Wild-type (BALB/c or C57/Bl6), CD74-KO (Shachar and Flavell,
1996), CD44-KO (Teder et al., 2002), and MIF-KO (Bozza et al.,
1999) mice were bred at the Yale Animal Resource Center. The KO
strains were in BALB/c or C57/Bl6 backgrounds (each at generation
N10). Mouse embryonic fibroblasts (MEFs) were prepared as de-
scribed (Fingerle-Rowson et al., 2003). Initial studies revealed no
differences in MIF signaling responses of cells derived from mice
of the BALB/c or C57/Bl6 backgrounds. Primary macrophages
from peritoneal exudate fluid were obtained as described previously
(Calandra et al., 1994). Mouse studies were approved by the Yale
Institutional Animal Use and Care Committee.
Plasmid DNA Vectors
The pcDNA3.1-CD74 plasmid was constructed by inserting a full-
length human CD74 cDNA fragment (1–232 aa) into the pcDNA3.1/V5-
His-TOPO vector (Invitrogen) (Leng et al., 2003). The pTracer-CD44
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poietic form of CD44 (CD44H, 1–361 aa) and a truncated CD44 lack-
ing the cytoplasmic domain (CD44D67, 1–294 aa), respectively, were
created by subcloning into the pTracer-SV40 vector (Invitrogen)
a human full-length CD44 cDNA or a CD44 cDNA created by sub-
stitution of a stop codon for cysteine 295 via site-directed
mutagenesis (Jiang et al., 2002). Structural fidelity was confirmed
by DNA sequencing. Figure 1 illustrates the CD74 and CD44 cDNA
constructs.
Creation of Stable Transformants
COS-7/M6 cells, which express neither CD74 nor CD44 (Figure 2;
Jiang et al., 2002), were stably transfected with pcDNA3.1-CD74,
pTracer-CD44, pcDNA3.1-CD74 plus pTracer-CD44, or pcDNA3.1-
CD74 plus pTracer-CD44D67 with the LipofectAMINE PLUS Kit (Invi-
trogen). Stable transformants were selected by culture in G418
(1.5 mg/ml, Sigma). The different transformants were subcloned
and stable expression confirmed periodically by immunoblotting
with human CD74 antibody (BD Pharmingen) and human CD44 anti-
body (sc-7297, Santa Cruz). Clones stably expressing immuno-
equivalent levels of CD74 and CD44 were used for functional stud-
ies. COS-7/M6 cells were used as negative controls, and HeLa cells
(Bouchard and Racaniello, 1997) expressing CD44 were used as
positive controls.
Flow Cytometry
Washed cells (w4.0 3 105) were resuspended in PBS/2% FBS and
stained on ice for 30 min with isotypic controls, human CD74, human
CD44, or mouse CD44 (BD Pharmingen) antibodies conjugated with
FITC or Alexa 488-labeled MIF (Leng et al., 2003). The labeled cells
were studied with a FACS-Calibur (BD Pharmingen) and the data
were analyzed with CellQuest software (BD Pharmingen).
Signal Transduction Assays
Cells were stimulated with native sequence, recombinant human
MIF (for COS-7 transformants) or mouse MIF (for MEFs and macro-
phages) produced in our laboratory (Bernhagen et al., 1994). The
human CD74 ectodomain (CD7473-232) was prepared recombinantly
in soluble form (sCD74) as described previously (Leng et al., 2003).
In a typical experiment, 2 3 106 cells were rendered quiescent by
incubation in low serum for 16 hr prior to stimulation with MIF for
5–30 min (Mitchell et al., 1999). Cells then were harvested and lysed
in buffer containing 50 mM HEPES (pH 7.5), 150 mM NaCl, 1.5 mM
MgCl2, 1 mM EGTA, 1% Glycerol, and 1% Triton X-100, and freshly
added phosphatase and proteinase inhibitors (1 mM orthovanan-
date, 10 mM NaF, 10 mg/ml leupeptin, 25 mg/ml aprotinin, and
50 mg/ml PMSF). For immunoblotting, 15–20 mg of cell lysate proteins
were separated by 10% SDS-PAGE and transferred to PVDF Immo-
bilon-P transfer membranes (Millipore). The blots were developed
with specific primary antibodies that included a pair of phospho-
ERK1and ERK2 (sc-7383, Santa Cruz) and (total) ERK1 and ERK2
(sc-94, Santa Cruz) antibodies, phospho-Src (Tyr416, Cell Signaling)
and Src (GD11, Upstate) antibodies, and GAPDH antibodies (Cell
Signaling). The ECL detection reagents (Amersham) were used to
visualize bands. The blots displayed are representative of stimula-
tion studies that were performed at least three times. For quantita-
tion of signal intensity, western blots were scanned and analyzed
as recently described (McDevitt et al., 2006). The ratio between
phosphorylated to the total kinase protein was determined and ex-
pressed as a fold-change for each lane. The p values were calcu-
lated for each of the comparisons shown from multiple experiments
(Student’s t test).
The serine phosphorylation of CD74 and CD44 was quantified by
specific sandwich ELISA (Perez et al., 2003). 96-well microtiter
plates were coated with 1–2 mg/ml of CD74 or CD44 antibody at
4C overnight. Lysates from MIF-stimulated or control cultures
were added to antibody-coated wells in triplicate and incubated at
4C overnight. After several washes (0.5% Tween-20 in PBS),
0.2 mg/ml phospho-serine antibody (Hypromatrix) conjugated with
horseradish peroxidase was added, and immunoreactivity was mea-
sured by the TMB reagent (DakoCytomation) and the data were an-
alyzed with SpectraMax Plus (Molecular Devices). Phospho-serine
values were expressed as relative ELISA absorbance for cell treat-
ment versus nontreatment.Protein kinase inhibition was performed by preincubating cells for
30–120 min with 20 mM of the PKA inhibitor H-89, 10 mM of the PKC
inhibitor RO-31-2880, or 10 mM of the Src inhibitor PP2 (Calbiochem)
(Faltynek et al., 1995). Cell lysates were collected and analyzed by
immunoblots with a pair of phospho-PKA and (total)-PKA anti-
bodies, a pair of phospho-PKC (all from Cell Signaling) and (total)-
PKC (Santa Cruz) antibodies, or phospho-Src and GAPDH anti-
bodies.
siRNA Studies
An siRNA specific for Src and a nontargeting siRNA control were ob-
tained from Dharmacon (Iversen et al., 2004). Cells were transfected
with siRNA with RNAiFect (Qiagen) for 24 hr. The cells then were in-
cubated in DMEM/0.3% FBS for 19 hr prior to stimulation with MIF
(100 ng/ml) for 30 min. Cell lysates were analyzed with immunoblots
with phospho-Src, Src (total), GAPDH, phospho-ERK1 and ERK2,
and total ERK1 and ERK2 antibodies.
Apoptosis Studies
Cells (23 106) cultured in 10 cm plates were treated for 24 hr with the
apoptosis inducers 1 mM sodium nitroprusside (SNP, Sigma) and
2 mg/ml camptothecin (Sigma) (Hudson et al., 1999; Mitchell et al.,
2002). Caspase-3 activity was analyzed with a colorimetric assay
kit (R&D Systems). Cytoplasmic p53 content was analyzed as de-
scribed previously (Mitchell et al., 2002) by immunoblotting of cyto-
solic fractions with a pair of phospho-p53 (Ser15) (R&D Systems)
and total p53 antibodies (Cell Signaling). In vivo apoptosis studies
followed the procedures of Mitchell et al. (2002) and were conducted
after i.p. injection of 15 mg/kg lipopolysaccharide (LPS) (E. coli
0111:B4; Sigma). Mice were sacrificed 24 hr after priming, and the
peritoneal macrophages were collected and immediately analyzed
for apoptosis by an oligonucleosome ELISA (Roche Diagnostics).
Primary macrophages also were immunostained by Alexa 488-con-
jugated, Annexin V (Invitrogen), and apoptotic cells were enumer-
ated by fluorescence microscopy.
Supplemental Data
Three Supplemental Figures can be found with this article online at
http://www.immunity.com/cgi/content/full/25/4/595/DC1/.
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